Jason Drew Smith sold $147k of URGN
General Counsel at UroGen Pharma Ltd.. 7,479 shares at an average of $19.69, traded Feb 3, 2026, filed Feb 11, 2026.
Score components
- +15RoleOfficer
- +11Trade size$147k at market
- +5Share of holdings soldSold 13% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -12.8%, 3m +46.4%, 6m +131.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-003778, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2026 | MOption exercise Ordinary Shares | +5,500 | - | - | 55,472 | Feb 11, 2026 |
| Feb 3, 2026 | SOpen-market sale Ordinary Shares | -2,654 | $19.69 | $52k | 52,934 | Feb 11, 2026 |
| Jan 31, 2026 | MOption exercise Ordinary Shares | +3,333 | - | - | 58,805 | Feb 11, 2026 |
| Feb 3, 2026 | SOpen-market sale Ordinary Shares | -1,608 | $19.69 | $32k | 51,326 | Feb 11, 2026 |
| Jan 31, 2026 | MOption exercise Ordinary Shares | +6,667 | - | - | 49,972 | Feb 11, 2026 |
| Feb 3, 2026 | SOpen-market sale Ordinary Shares | -3,217 | $19.69 | $63k | 55,588 | Feb 11, 2026 |
| Jan 31, 2026 | MOption exercise Restricted Stock Unitsderivative | -5,500 | $0.00 | $0 | 5,500 | Feb 11, 2026 |
| Jan 31, 2026 | MOption exercise Restricted Stock Unitsderivative | -3,333 | $0.00 | $0 | 6,667 | Feb 11, 2026 |
| Jan 31, 2026 | MOption exercise Restricted Stock Unitsderivative | -6,667 | $0.00 | $0 | 0 | Feb 11, 2026 |
| Jan 31, 2026 | AGrant or award Restricted Stock Unitsderivative | +32,609 | $0.00 | $0 | 32,609 | Feb 11, 2026 |
Related signals
Other insiders at UroGen Pharma Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | URGNsell UroGen Pharma Ltd. | Chris Degnan Chief Financial Officer | $81k 2,202 shares | -33% | |
| 14Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $37k 871 shares | -1% | |
| 16Weak | UroGen Pharma Ltd. | Jason Drew Smith General Counsel | $65k 1,519 shares | -3% | |
| 60Notable | URGNsell UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $2.9M 60,677 shares | -51% | |
| 11Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $400k 10,000 shares | -8% | |
| 10Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $350k 10,000 shares | -7% | |
| 11Weak | URGNsell UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $143k 5,222 shares | -4% | |
| 9Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $300k 10,000 shares | -7% | |
| 34Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $145k 7,373 shares | -5% | |
| 8Weak | UroGen Pharma Ltd. | Mark Schoenberg Chief Medical Officer | $250k 10,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.